A Self-controlled Study of the Effect of Partial Spectral Absence of Visible Light on the Pupil
The Impact of Partial Visible Light Spectrum Absence on Pupil Response and Autonomic Nervous System Excitability: A Cross-Over Randomized Controlled Trial
1 other identifier
interventional
66
0 countries
N/A
Brief Summary
Previous studies have shown that the spectrum of light influences myopia. LED lights with a partially absent light spectrum increase the risk of myopia progression compared to LEDs with a full spectrum, potentially mediated by the excitability of the parasympathetic nervous system. This study intends to compare pupil size and area, as well as parameters regulated by the autonomic nervous system (such as skin bioelectrical activity and heart rate), between LEDs with a full visible spectrum and LEDs with a partially absent spectrum around 470nm and 730nm. We aim to elucidate the physiological mechanism underlying the effect of light spectrum on pupil changes and myopia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2024
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 8, 2024
CompletedFirst Posted
Study publicly available on registry
July 15, 2024
CompletedStudy Start
First participant enrolled
July 24, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2024
CompletedJuly 15, 2024
July 1, 2024
1 month
July 8, 2024
July 12, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
pupil size
The pupil diameter is measured in real-time using the Eyelink Portable Duo eye tracker.
5 minutes
Secondary Outcomes (7)
Skin conductance response
5 minutes
Respiratory movement
5 minutes
Pulse pressure waveform
5 minutes
Spherical equivalent refraction
5 minutes
Uncorrected visual acuity
5 minutes
- +2 more secondary outcomes
Study Arms (2)
full spectrum light group
EXPERIMENTALSubjects were asked to stay in a resting state for 5 minutes in a dark room, then turn on the full-spectrum light and adapt to the light environment for 5 minutes, and then take measurements for 5 minutes. After wash-out in the dark room for 5 minutes, change the light to ordinary LED lamp and repeat the above test steps for measurement.
ordinary LED light group
EXPERIMENTALSubjects were asked to stay in a resting state for 5 minutes in a dark room, then turn on the ordinary LED lamp and adapt to the light environment for 5 minutes, and then take measurements for 5 minutes. After wash-out in the dark room for 5 minutes, change the light to full-spectrum light and repeat the above test steps for measurement.
Interventions
Subjects will stay in a room with full spectrum light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
Subjects will stay in a room with ordinary LED light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
Eligibility Criteria
You may qualify if:
- \. Age 7-45 years 2. Able to wear multi-channel physiological measurement devices and cooperate with experimental procedures.
- \. Binocular? spherical power between -0.50 to -5.00 diopters, and cylinder power no more than -1.50 diopters.
- \. Voluntarily participate in this study with informed consent form signed.
You may not qualify if:
- \. History of diseases affecting autonomic nervous system function, such as depression and anxiety.
- \. History of eye diseases such as strabismus, amblyopia, keratitis, and glaucoma, which are unsuitable for eye movement test.
- \. History of major systemic diseases or surgeries such as cranial surgery, myocardial infarction, or stroke.
- \. Systemic medication history that may affect autonomic nervous system function, including but not limited to antidepressants, antihistamines, anticholinergics, antipsychotics, and sedative-hypnotic drugs like diazepam or lorazepam.
- \. Use of eyedrops such as mydriatics or miotics that will affect pupil size. 6. Having difficulty in understanding and cooperating with the trial, such as those with disabilities, communication barriers, or those unable to undertake examinations.
- \. Other contradictions that the physician may consider inappropriate for enrolment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 8, 2024
First Posted
July 15, 2024
Study Start
July 24, 2024
Primary Completion
August 31, 2024
Study Completion
September 30, 2024
Last Updated
July 15, 2024
Record last verified: 2024-07